BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-111@pharmaconomics
DTSTAMP:20260707T034515Z
DTSTART;VALUE=DATE:20261116
DTEND;VALUE=DATE:20261117
SUMMARY:MRK Phase 2 — Tulisokibart
DESCRIPTION:Phase 2 trial results for Tulisokibart in Hidradenitis Suppurativa are due Nov 16\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06956235\n\nTrack it: https://www.pharmaconomics.com/e/111
URL:https://www.pharmaconomics.com/e/111
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:MRK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR